BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 5, 2026
Home » Topics » Drugs » Degradation inducer

Degradation inducer
Degradation inducer RSS Feed RSS

Cancer

Treeline Biosciences reports TEAD degraders

March 20, 2026
Treeline Biosciences Inc. has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to transcriptional enhancer factor TEF (TEAD)-targeting moiety potentially useful for the treatment of cancer.
Read More
Immune

Innocare presents new VAV1 degradation inducers

March 19, 2026
Beijing Innocare Pharma Tech Co. Ltd. and Innocare Pharma Inc. have patented molecular glue degraders acting as VAV1 degradation inducers. They are reported to be useful for the treatment of autoimmune disease and inflammatory disorders.
Read More
Cancer

University of Texas patents new YAP1 PROTACs

March 17, 2026
A University of Texas System patent describes new YAP1 degradation inducing proteolysis targeting chimeras (PROTACs) designed for use in the treatment of cancer.
Read More
Immune

VAV1 degradation inducers reported in new Humanwell Healthcare patents

March 11, 2026
Humanwell Healthcare (Group) Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN)-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are reported to be useful for the treatment of autoimmune disease, cancer, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, periodontitis, psoriasis, rheumatoid arthritis and type I diabetes, among others.
Read More
Cancer

Gilead Sciences discovers KRAS G12D mutant inhibitors

March 6, 2026
A patent from Gilead Sciences Inc. has divulged GTPase KRAS (G12D mutant) inhibitors and proteolysis targeting chimeras (PROTACS) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS (G12D mutant)-targeting moiety through linker.
Read More
Cancer

Risen Pharma synthesizes PROTAC KRAS degraders

March 5, 2026
A Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. patent describes the discovery of new proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS-targeting moiety. They are reported to be useful for the treatment of cancer.
Read More
Microscopic image of acute myeloid leukemia (AML) cells.
Cancer

Dual degrader shows activity in acute myeloid leukemia models

March 4, 2026
No Comments
Researchers in China reported the discovery and preclinical characterization of ZX-079, a novel BRD4/CBP PROTAC degrader.
Read More
Leukemia illustration
Cancer

Newly described selective CDK6 degrader exhibits potential in leukemia models

March 3, 2026
No Comments
Researchers from Specally (Wuhan) Life Technology Co. Ltd. have disclosed the discovery and preclinical profile of WWZ-11-098, a non-palbociclib-based, selective cyclin-dependent kinase 6 (CDK6) degrader in models of leukemia.
Read More
Cancer cell in the cross-hairs
Immuno-oncology

ARV-6723 shows robust efficacy in solid tumors

March 2, 2026
No Comments
Mitogen-activated protein kinase kinase kinase kinase 1 (HPK1) is a serine/threonine protein kinase that is expressed in the hematopoietic compartment, exerting regulatory functions in myeloid and innate immune cells. It has been associated with decreased T-cell activation and proliferation.
Read More
Cancer

Triana Biomedicines patents ALK degradation inducers

Feb. 27, 2026
Triana Biomedicines Inc. has disclosed ALK tyrosine kinase receptor degradation inducers intended for use in the treatment of cancer.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 19 20 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 31, 2026
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • Illustration of a nerve cell with DNA double helix

    Molecular signatures show subtypes in neurodegenerative diseases

    BioWorld Science
    Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing